The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Exelixis Inc

  • EXEL
  • NASDAQ
  • Consumer Products
  • Latest 1.70
  • Currency US$
  • Change -0.02
  • Percent Change -1.163 %
  • Volume 7,171,014
  • Fri Sep 19, 2014 12:15 PM EDT NASDAQ data delayed 15 minutes.
  • Open 1.71
  • Previous Close 1.72
  • High 1.74
  • Low 1.68
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High01/22 8.41
  • 52-week Low09/16 1.60
  • Beta 2.126
  • Market Cap 330.84M
  • EPS -1.51
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $26,590,000
  • Earnings $-274,650,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $157,530,000
  • Current Ratio 4.20

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $497,560,000
  • Liabilities $426,080,000
  • Liabilities-to-Equity Ratio 5.96

Price Ratios

  • Price to Sales 12.44
  • Price to Book 4.63
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Jul 31 $-0.39 Oct 29 $-0.34
Surprises Jul 31 -2.56% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Sep 20, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Exelixis Inc. is a leader in the fields of model system genetics and comparative genomics. These fields involve the systematic study of simple organisms, such as fruit flies, nematodes, mice, zebrafish and simple plants, to rapidly and efficiently determine gene function and establish its commercial utility in humans and other commercially important biological systems. The proprietary technologies provide a rapid, efficient and cost-effective way to move beyond DNA sequence data to understand the function of genes and the proteins that they encode.

Related Securities
Symbol Type Latest % Chg

Officers

  • Stelios Papadopoulos Chairman
  • Michael M. Morrissey President and Chief Executive
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

210 E. GRAND AVE
SOUTH SAN FRANCISCO, CA
94080

Phone: (650)-837-7000
Fax: (650)-8378300

cbutler@exelixis.com
www.exelixis.com

Ideas & Discussion

Live Discussion of EXEL on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.